TBK1/IKKε-IN-5 (compound 1 in patent WO 2016049211) is a potent dual TBK1 and IKKε inhibitor, with IC50 of 1 nM and 5.6 nM for TBK1 and IKKε, respectively.

SC-514 (SC 514; SC514) is a novel, potent, orally bioactive, selective and reversible, and ATP-competitive IKK-2 inhibitor with potential anti-inflammatory activity.

IMD-0354 (IMD0354; IMD-0354) is a novel, potent and selective IKKβ inhibitor with potential anti-inflammatory activity.

NF-κB-IN-1 is a novel and potent NF-κB signaling pathway inhibitor can directly inhibit IKK and block NF- κ B activation.

BMS-345541 (BMS345541; BMS 345541) is a novel, highly potent and selective IKK-1/2 inhibitor with potential anticancer and anti-inflammatory activity.

Mesalamine (also named as 5ASA; Z-206; AJG-501; MAX-002; 5-aminosalicylic acid; Asacol; mesalazine; 5-ASA) is a specific and orally bioavailable inhibitor of TNFα-induced IKK activity with potential anti-inflammatory activity.

BAY 11-7085 (BAY-11-7085; BAY 117085) is a novel, potent, soluble, irreversible inhibitor of TNFα-induced IκBα phosphorylation with potential anticancer activity.

BAY 11-7082 (BAY-11-7082; BAY-117082) is a novel and potent NF-κB inhibitor with potential anti-inflammatory and anticancer activity.

Ertiprotafib (PTP-112; PTP112) is a novel and potent Protein Tyrosine Phosphatase 1B Inhibitor (PTP1B inhibitor) with the ability to normalize the plasma glucose and insulin levels in diabetic animal models.

LY2409881 trihydrochloride (LY-2409881; LY 2409881), the trihydrochloride salt of LY-2409881, is a novel, potent and selective IKK2 ( IκB kinase β) inhibitor with potential anticancer and anti-inflammatory activity.